A Decade of Research on nab®-Chemotherapy
Clinical & Preclinical Bibliography
Breast Cancer

Metastatic - Monotherapy

Research Articles


Editorial


Taxane-refractory


Reviews


Scheff RJ. Breast cancer and the new taxanes: focus on nab-paclitaxel. Community Oncol. 2006;3(7 suppl 8).


Taxane-refractory


Case Reports


Conference Proceedings


Breast Cancer (cont)

Metastatic - Monotherapy (cont)

Conference Proceedings (cont)


Metastatic - Combination Therapy

Research Articles


Case Reports


Conference Proceedings


Metastatic - Combination Therapy (cont)

Conference Proceedings (cont)


Triple Negative Breast Cancer

Blackwell KL, et al. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)L and carboplatin (C)bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 1070.

Hamilton EP, Kimmick, GG, Desai N, et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP/L) and carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 1109.

Adjuvant - Monotherapy

Conference Proceedings


Adjuvant - Combination Therapy

Research Articles


Case Reports


Breast Cancer (cont)

Adjuvant - Combination Therapy (cont)

Conference Proceedings

Inflammatory Breast Cancer

Bernstein JA and Mehta R. In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) -> weekly carboplatin and albumin-bound paclitaxel (nab-T/C)/trastuzumab (H)/bevacizumab (B) in large and inflammatory breast cancer (BC): A phase II study. Presented at: Proceedings of the 43rd American Society of Clinical Oncology Annual Meeting (ASCO); June 1-5, 2007; Chicago IL, J Clin Oncol 25(18s), abstr 11078.


Melisko ME, Greenberg S, Dickler MN, et al. Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 579.


Von Minckwitz G. NE II: An investigational randomized phase II study on epirubicin (E) plus cyclophosphamide (C) or CMF versus nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly nonfrail patients with an increased risk for relapse of a primary carcinoma of the breast. Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr TPS104.

Neoadjuvant - Combination Therapy

Research Articles


Neoadjuvant - Combination Therapy (cont)

Conference Proceedings


Mirozek E, Lustberg MB, Knopp MV, et al. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 604.


Breast Cancer (cont)
Neoadjuvant - Combination Therapy (cont)
Conference Proceedings (cont)
Yardley DA., Daniel, BR, Inhorn RC, et al. SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 10574.

Triple Negative Breast Cancer
Connolly RM, Jeter S, Zorzi J, et al. A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBRCRC008). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr TPS111.


Inflammatory Breast Cancer
Somlo G, Frankel PH, Vora L, et al. Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin +/- trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 540.

Genitourinary Cancer
Monotherapy

Case Reports

Conference Proceedings
Benigio BD, Burrell MO, Daugherty P, et al.. A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer. Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 5011.

Conference Proceedings (cont)

Gynecologic Cancer
Monotherapy

Research Articles

Reviews
Head and Neck Cancer

Monotherapy

Research Articles


Combination Therapy

Conference Proceedings


Kuperman, D, et al. Clinical response rate at primary tumor site by WHO criteria following an induction chemotherapy regimen of weekly nanoparticle albumin-bound (nab)-paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and necksquamous cell carcinoma (HNSCC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr 5564.

Lung Cancer - Advanced (cont)

NSCLC - Combination Therapy

Research Articles


Conference Proceedings


Keedy V, et al. A phase I study of nab-paclitaxel (nP) with carboplatin(C) & thoracic radiation (TRT) in patients with locally advanced NSCLC. Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 28(15s), abstr e14675.

Socinski MA, Bondarenko IN, Karaseva NA, et al. Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with chemoraph-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 46th American Society of Clinical Oncology Annual Meeting (ASCO); June 4-8, 2010; Chicago IL, J Clin Oncol 27(15s), abstr LBA7511.
Clinical References

Pancreatic Cancer - Advanced/Metastatic (cont)

Combination Therapy (cont)


Prostate Cancer

Monotherapy

Research Articles


Conference Proceedings


Solid Tumors

Monotherapy

Research Articles

Primary Cancer Type: Breast


Primary Cancer Type: Colorectal


Primary Cancer Type: Lung


Primary Cancer Type: Melanoma


Pancreatic Cancer - Advanced/Metastatic

Combination Therapy


Solid Tumors

Monotherapy

Research Articles

Primary Cancer Type: Breast


Primary Cancer Type: Colorectal


Primary Cancer Type: Lung


Primary Cancer Type: Melanoma

Solid Tumors (cont)

Monotherapy (cont)

Research Articles (cont)

Primary Cancer Type: Prostate

Reviews

Conference Proceedings


Combination Therapy

Research Articles

Primary Cancer Type: Lung


Conference Proceedings


Primary Cancer Type: Lung

Health Economics

Research Articles


Conference Proceedings


Forcage GW, Pummire BA, Gilbertson VL. A taxane total cost of care analysis in metastatic breast cancer: results of private payer claims data. Presented at Proceedings of the 32nd Annual San Antonio Breast Cancer Symposium (CRTC-AACR-SABCS); Dec 9–13, 2009; San Antonio TX, Cancer Res 69(24 suppl 1), abstr 1076.


Restenosis

Monotherapy

Research Articles

nab-Paclitaxel-related Publications

Breast Cancer
Monotherapy
Research Articles

Conference Proceedings


Combination Therapy
Research Articles

Conference Proceedings

Triple Negative Breast Cancer

Inflammatory Breast Cancer

Adrenocortical Cancer
Monotherapy
Conference Proceedings

Gynecologic Cancer
Monotherapy
Research Articles


Head and Neck Cancer
Combination Therapy
Conference Proceedings

Hepatic Cancer
Monotherapy
Conference Proceedings

Pancreatic Cancer
Monotherapy
Conference Proceedings

Solid Tumors
Monotherapy
Research Articles


Solid Tumors (cont)

Monotherapy (cont)

Conference Proceedings

Desai N, Yao Z, Soon-Shiong P. Evidence of enhanced in vivo efficacy at maximum tolerated dose (MTD) of nanoparticle paclitaxel (ABI-007) and taxol in 5 human tumor xenografts of varying sensitivity to paclitaxel. Presented at: Proceedings of the 38th American Society of Clinical Oncology Annual Meeting; May 18-21, 2002; Orlando FL, ASCO, abstr 462.


Combination Therapy

Conference Proceedings


nab Technology/Mechanism of Action/SPARC

Monotherapy

Research Articles


Research Articles


Conference Proceedings


nab Technology/Mechanism of Action/SPARC (cont)

Monotherapy (cont)

Conference Proceedings


Trieu V, Frankel T, Labao E, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Presented at: Proceedings of the 96th American Association for Cancer Research Annual Meeting; Apr 16-20, 2005; Anaheim CA, AACR, abstr 5584.

Trieu V, Hwang L, Desai N. Enhancement of antitumor activity of nab-paclitaxel through targeting of SPARC. Presented at: Proceedings of the 33th European Society for Medical Oncology Congress (ESMO); Sept 12-16, 2008; Stockholm Sweden, Ann Oncol 19(Suppl 8), abstr 102P.


Combination Therapy

Conference Proceedings


Pipeline Publications

Monotherapy

Research Articles


Conference Proceedings


Pipeline Publications (cont)

Monotherapy (cont)

Conference Proceedings (cont)


Combination Agent

Conference Proceedings


